Infliximab treatment for severe orogenital ulceration in Behçet's disease [5]

British Journal of Dermatology

Volumn 153, Issue 5, 2005, Pages 1073-1075

  Connolly, M ^a   Armstrong, J S ^b   Buckley, D A ^b  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

^b GREAT WESTERN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COLCHICINE; CYCLOSPORIN A; INFLIXIMAB; LEFLUNOMIDE; LIDOCAINE; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE; THALIDOMIDE;

ADULT; ANAMNESIS; BEHCET DISEASE; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; FEMALE; HISTOLOGY; HUMAN; LETTER; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SKIN BIOPSY; TREATMENT WITHDRAWAL; UROGENITAL ULCER;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BEHCET SYNDROME; FEMALE; GENITAL DISEASES, FEMALE; HUMANS; ORAL ULCER; ULCER;

EID: 27544493175     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06914.x     Document Type: Letter

References (13)

1. Sayinalp N, Özcebe OI, Özdemir O et al. Cytokines in Behçet's disease. J Rheumatol 1996; 23:321-2.
2. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990; 335:1078-80.
3. Scully C. The oral cavity. In: Textbook of Demiatology (Champion RH, Burton JL, Burns DA, Breathnach SM, eds), 6th edn. Oxford: Blackwell Science 1998; 3072-4.
4. Jenkins JS, Powell RJ, Allen BR et al. Thalidomide in severe orogenital ulceration. Lancet 1984; ii:1424-6.
5. Chaudhari U, Romano P, Mulcahy LD et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357:1842-7.
6. Gottlieb AB, Chaudhari U, Mulcahy LD et al. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol 2003; 48:829-35.
7. Haugeberg G, Velken M, Johnsen V. Successful treatment of genital ulcers with infliximab in Behçet's disease. Ann Rheum Dis 2004; 63:744-5.
8. Robertson LP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab. Rheumatology (Oxford) 2001; 40:473-4.
9. Goossens PH, Verburg RJ, Breedveld FC. Remission of Behçet's syndrome with tumour necrosis factor Ot blocking therapy. Am Rheum Dis 2001; 60:637.
10. Estrach C, Mpofu S, Moots RJ. Behçet's syndrome: response to infliximab after failure of etanercept. Rheumatology (Oxford) 2002; 41:1213-4.
11. Travis SPL, Czajkowski M, McGovern DPB et al. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor α antibody. Gut 2001; 49:725-8.
12. Sfikakis PP, Theodossiadis PG, Katsiari CG et al. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 2001; 358:295-6.
13. Sfikakis PP. Behçet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 2002; 61 (Suppl. 2):S51-3.